Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711912 | 0.92 | EPHX1 (0.40) | EPHX1EPHX2RXFP1GRM4CYP1A2 | |
| SCHEMBL6708650 | 0.90 | ROCK2 (0.40) | EPHX1EPHX2RXFP1GRM4CYP1A2 | |
| SCHEMBL6714240 | 0.86 | RXFP1 (0.42) | RXFP1GRM4HDAC3HDAC1 | |
| SCHEMBL6712110 | 0.85 | EPHX1 (0.42) | EPHX1EPHX2RXFP1GRM4ALOX15 | |
| SCHEMBL6707646 | 0.85 | RXFP1 (0.45) | RXFP1GRM4HDAC1RAB9A | |
| SCHEMBL6709851 | 0.84 | RXFP1 (0.39) | RXFP1GRM4 | |
| SCHEMBL6708004 | 0.83 | RXFP1 (0.41) | RXFP1GRM4 | |
| SCHEMBL6710017 | 0.81 | RXFP1 (0.45) | RXFP1GRM4 | |
| SCHEMBL6708533 | 0.81 | USP2 (0.41) | RXFP1GRM4 | |
| SCHEMBL6713205 | 0.80 | GRM4 (0.52) | RXFP1GRM4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | EPHX1 1869/4885EPHX2 2941/4885RXFP1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.